#	Pagina
attuale pagina	/open-h2020/projects/223124/index.html
-1	/open-consip/fornitori/2017/profilo-03658590611/index.html

Opendata, web and dolomites

Vacc-iNTS SIGNED

Advancing a GMMA-based vaccine against invasive non-typhoidal salmonellosis through Phase 1 trial in Europe and sub-Saharan Africa

Total Cost €

EC-Contrib. €

Partnership

Views

Vacc-iNTS project word cloud

Explore the words cloud of the Vacc-iNTS project. It provides you a very rough idea of what is the project "Vacc-iNTS" about.

immunogenicity enteritidis proof generalized stage suited healthy blebs antibody experts data academia epidemiological bactericidal infectious gmp strengthen biology trial genetically countries accelerate saharan antibiotic clinical lt profit bacteria serum adults advancing vaccine lots limited fatality resource trials tackling difficult preclinical strains modified gap rate antibodies vacc immunogenic disease africa antigens levels roadblocks released rapid salmonellosis african 263 invasive integration generate bridges olds advocate transcriptomics sub advocacy ints modules membrane sonnei gmma industry scalable shigella deployment poor resistance serotypes network 20 deaths safety followed diagnosis proposes cellular typhimurium endemic drive typhoidal sero settings ssa collaborative animals outer manufacturing

Project "Vacc-iNTS" data sheet

The following table provides information about the project.

Coordinator	SCLAVO VACCINES ASSOCIATION Organization address address: PIAZZA LA LIZZA 7 city: SIENA postcode: 53100 website: www.sclavo.org/home contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Italy [IT]
Total cost	0 €
EC max contribution	6˙871˙188 € (0%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SC1-2018-Two-Stage-RTD
Funding Scheme	RIA-LS
Starting year	2019
Duration (year-month-day)	from 2019-10-01 to 2024-09-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	SCLAVO VACCINES ASSOCIATION SCLAVO VACCINES ASSOCIATION Organization address address: PIAZZA LA LIZZA 7 city: SIENA postcode: 53100 website: www.sclavo.org/home contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (SIENA)	coordinator	1˙152˙311.00
2	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD Organization address address: WELLINGTON SQUARE UNIVERSITY OFFICES city: OXFORD postcode: OX1 2JD website: www.ox.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (OXFORD)	participant	2˙227˙288.00
3	GSK VACCINES INSTITUTE FOR GLOBAL HEALTH SRL GSK VACCINES INSTITUTE FOR GLOBAL HEALTH SRL Organization address address: VIA FIORENTINA 1 city: SIENA postcode: 53100 website: www.nvgh.novartis.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (SIENA)	participant	1˙576˙515.00
4	THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE Organization address address: TRINITY LANE THE OLD SCHOOLS city: CAMBRIDGE postcode: CB2 1TN website: www.cam.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (CAMBRIDGE)	participant	545˙942.00
5	THE UNIVERSITY OF LIVERPOOL THE UNIVERSITY OF LIVERPOOL Organization address address: BROWNLOW HILL 765 FOUNDATION BUILDING city: LIVERPOOL postcode: L69 7ZX website: www.liverpool.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (LIVERPOOL)	participant	432˙034.00
6	UNIVERSITA DEGLI STUDI DI SIENA UNIVERSITA DEGLI STUDI DI SIENA Organization address address: VIA BANCHI DI SOTTO 55 city: SIENA postcode: 53100 website: www.unisi.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (SIENA)	participant	341˙017.00
7	KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY KUMASI KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY KUMASI Organization address address: PRIVATE MAIL BAG, UNIVERSITY POST OFFICE city: KUMASI postcode: ASH website: www.knust.edu.gh contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	GH (KUMASI)	participant	194˙226.00
8	UNIVERSITE OUAGA I PROFESSEUR JOSEPH KI-ZERBO UNIVERSITE OUAGA I PROFESSEUR JOSEPH KI-ZERBO Organization address address: . city: OUAGADOUGOU 03 postcode: 3 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BF (OUAGADOUGOU 03)	participant	192˙980.00
9	KENYA MEDICAL RESEARCH INSTITUTE KENYA MEDICAL RESEARCH INSTITUTE Organization address address: Off Mbagathi Way city: Nairobi postcode: 200 website: www.kemri.org contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	KE (Nairobi)	participant	107˙575.00
10	UNIVERSITY OF OTAGO UNIVERSITY OF OTAGO Organization address address: SAINT DAVID STREET city: DUNEDIN postcode: 9054 website: www.otago.ac.nz contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NZ (DUNEDIN)	participant	50˙000.00
11	PRINS LEOPOLD INSTITUUT VOOR TROPISCHE GENEESKUNDE PRINS LEOPOLD INSTITUUT VOOR TROPISCHE GENEESKUNDE Organization address address: Nationalestraat 155 city: ANTWERPEN postcode: 2000 website: www.itg.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (ANTWERPEN)	participant	31˙296.00
12	MMGH CONSULTING GMBH MMGH CONSULTING GMBH Organization address address: KUERBERGSTRASSE 1 city: ZURICH postcode: 8049 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CH (ZURICH)	participant	20˙000.00

Map

Project objective

Invasive non-typhoidal Salmonellosis (iNTS) is an important emerging Neglected Infectious Disease in resource-poor settings of sub-Saharan Africa (sSA). No vaccine is currently available. Estimated 263,000 iNTS deaths per year in <5 year olds, a 20% case fatality rate, difficult diagnosis and increasing antibiotic resistance strongly advocate for rapid development of an effective vaccine. Vacc-iNTS bridges the gap between preclinical and early clinical development of a novel vaccine against iNTS, based on GMMA (Generalized Modules for Membrane Antigens) from the most common African iNTS serotypes (Typhimurium and Enteritidis). The highly cost-effective GMMA-technology, developed by partner 2, is based on outer membrane blebs released by genetically modified bacteria. Clinical proof-of-concept for the GMMA-technology was achieved with a Shigella sonnei vaccine in European and African adults. In animals, iNTS-GMMA were highly immunogenic and induced antibodies with bactericidal activity against African iNTS strains. Simple, robust and scalable manufacturing processes for iNTS-GMMA, suited for sSA, have been developed. Vacc-iNTS proposes GMP manufacturing of clinical lots followed by a two-stage Phase 1 trial in healthy European and African adults to investigate safety and immunogenicity of the iNTS-GMMA vaccine. Analysis include serum antibody levels and functionality, cellular responses, transcriptomics and data integration through a systems biology approach. Sero-epidemiological analysis will be conducted to provide essential data for future Phase 2 and 3 trials. Vacc-iNTS will also strengthen a collaborative network of iNTS experts from academia, industry and non-profit including partners from disease-endemic countries of sSA. The network will generate data to accelerate further vaccine development, enhance awareness, drive advocacy and vaccine deployment in limited-resources disease-endemic countries, tackling major roadblocks in advancing a vaccine against iNTS.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VACC-INTS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VACC-INTS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination